The aim of this systematic review was to systematically analyse existing literature on the effect of GLP‐1 RA–based therapies on skeletal muscle mitochondrial function within people with obesity or T2DM or relevant disease animal or cell models of obesity or T2DM. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.